MX2023015076A - Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado. - Google Patents

Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado.

Info

Publication number
MX2023015076A
MX2023015076A MX2023015076A MX2023015076A MX2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A MX 2023015076 A MX2023015076 A MX 2023015076A
Authority
MX
Mexico
Prior art keywords
water content
preparing
radio
sup
low water
Prior art date
Application number
MX2023015076A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Jackson
Torgrim Engell
Graeme Mcrobbie
Alan Clarke
Julian Grigg
Imtiaz Ahmed Khan
Kristine Wikene
Jonathan Shales
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MX2023015076A publication Critical patent/MX2023015076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023015076A 2021-06-16 2022-06-16 Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado. MX2023015076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2108605.3A GB202108605D0 (en) 2021-06-16 2021-06-16 Effect of water content
PCT/EP2022/066483 WO2022263594A1 (en) 2021-06-16 2022-06-16 Method for preparing an [18f] radiolabelled compound with low water content during labelling step

Publications (1)

Publication Number Publication Date
MX2023015076A true MX2023015076A (es) 2024-01-18

Family

ID=76954450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023015076A MX2023015076A (es) 2021-06-16 2022-06-16 Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado.

Country Status (12)

Country Link
US (2) US20240366808A1 (enExample)
EP (1) EP4355715A1 (enExample)
JP (1) JP2024522770A (enExample)
KR (1) KR20240021888A (enExample)
CN (1) CN117500773A (enExample)
AU (1) AU2022294052A1 (enExample)
BR (1) BR112023026514A2 (enExample)
CA (1) CA3223802A1 (enExample)
GB (1) GB202108605D0 (enExample)
IL (1) IL308917A (enExample)
MX (1) MX2023015076A (enExample)
WO (1) WO2022263594A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0520527D0 (en) 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
EP2053033A1 (en) * 2007-10-26 2009-04-29 Bayer Schering Pharma AG Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
EP2657213A1 (en) * 2012-04-24 2013-10-30 Institut National de la Santé et de la Recherche Medicale Labelled quinoxaline derivatives as multimodal radiopharmaceuticals and their precursors
EP2880005B1 (en) * 2012-07-30 2016-05-25 Technical University of Denmark Radiofluorination method
CN107207379B (zh) * 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3423113B1 (en) * 2016-02-29 2020-09-02 Oncodesign S.A. Radiolabeled macrocyclic egfr inhibitor
US11583596B2 (en) * 2017-09-26 2023-02-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Radiolabeled Darapladib and analogs thereof and their use as imaging compounds

Also Published As

Publication number Publication date
KR20240021888A (ko) 2024-02-19
US20240366808A1 (en) 2024-11-07
AU2022294052A1 (en) 2023-12-14
CN117500773A (zh) 2024-02-02
JP2024522770A (ja) 2024-06-21
WO2022263594A1 (en) 2022-12-22
IL308917A (en) 2024-01-01
CA3223802A1 (en) 2022-12-22
BR112023026514A2 (pt) 2024-03-05
GB202108605D0 (en) 2021-07-28
EP4355715A1 (en) 2024-04-24
US20250312494A1 (en) 2025-10-09

Similar Documents

Publication Publication Date Title
AU2003264043A1 (en) Method of making mercaptoalkylalkoxysilanes
WO2001018161A3 (en) Process for the preparation of conjugated linoleic acid (cla)
MX2023015076A (es) Metodo para preparar un compuesto radioetiquetado [18f] con bajo contenido de agua durante la etapa de etiquetado.
EP0464325A3 (en) Process for the preparation of l-ornithine salts
KR850004502A (ko) L-카르니틴 및 그 유도체의 제조방법
AU2001264234A1 (en) Microcapsule suspension liquid and process for production thereof
Tanaka et al. Selenocysteine
CN106478431B (zh) 一种合成反式环己二甲胺的方法
CN109748812A (zh) 一种丙氨酸铁络合物添加剂的制备方法
ZA200107763B (en) Process for producing non-proteinogenic L-amino acids by fermentation.
KR102127104B1 (ko) 5-아미노레불린산 또는 그 염의 제조 방법
WO2003059889A1 (en) Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same
CN109182406A (zh) 一种l-天门冬氨酸的制备方法
GB1371688A (en) Process for preparing benzoxazolones-2- and benzothiazolones-2
CN101509022A (zh) 一种提高l-色氨酸提取收率的方法
ES8609208A1 (es) Procedimiento de preparacion de p-aminofenoles
RU2008146193A (ru) Способ получения грамицидина с при глубинном выращивании культуры - продуцента bacillus brevis
WO2006003395A3 (en) Molten salts, method of their production and process for generating hydrogen peroxide
JPS5940823B2 (ja) アミノ酸の製法
ES8308802A1 (es) "un procedimiento mejorado para producir en continuo persulfato de sodio".
Cohen et al. Mercaptan Catalysis in Thermoneutral Free Radical Exchange: R·+ R* H [UNK] rh+ R*·
JPH0730006B2 (ja) トランス−４−シアノシクロヘキサン−１−カルボン酸の製造法
HRP20031004A2 (en) Method for producing an essentially chlorite-free,stable, aqueous chlorine-oxygen solution, the chlorine-oxygen solution obtained by means of said method, and the use of the same
JPS5991890A (ja) Ｌ−フエニルアラニンの製造方法
AR016252A1 (es) PROCEDIMIENTO PARA LA PRODUCCIoN DE ÁCIDO TARTÁRICO A PARTIR DE UNA MATERIA PRIMA QUE CONTIENE TARTRATO ÁCIDO DE POTASIO